Michael J Pishvaian

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. pmc A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 70:843-53. 2012
  2. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
  3. pmc A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 71:627-33. 2013
  4. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
  5. pmc Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine
    Michael Harris
    aInnovation Center for Biomedical Informatics bLombardi Comprehensive Cancer Center, Developmental Therapeutics Program cDepartment of Neurology, Georgetown University Medical Center dDepartment of Mathematics and Statistics, Georgetown University, Washington, District of Columbia eESAC Inc, Rockville fUS Food and Drug Administration, Silver Spring, Maryland, USA
    Pharmacogenet Genomics 24:81-93. 2014
  6. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
  7. pmc The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway
    M Carla Cabrera
    Department of Oncology, Georgetown University, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 5:810-21. 2012

Collaborators

Detail Information

Publications7

  1. pmc A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 70:843-53. 2012
    ..We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors...
  2. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
    ..The authors conducted a phase 1 study to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone...
  3. pmc A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 71:627-33. 2013
    ....
  4. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
    ..The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusions of obatoclax, respectively...
  5. pmc Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine
    Michael Harris
    aInnovation Center for Biomedical Informatics bLombardi Comprehensive Cancer Center, Developmental Therapeutics Program cDepartment of Neurology, Georgetown University Medical Center dDepartment of Mathematics and Statistics, Georgetown University, Washington, District of Columbia eESAC Inc, Rockville fUS Food and Drug Administration, Silver Spring, Maryland, USA
    Pharmacogenet Genomics 24:81-93. 2014
    ..The aim of our in-silico study was to identify gene variants significantly associated with gemcitabine response that may help to personalize treatment in the clinic...
  6. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
    ..This Pilot study assessed the safety of concurrent full-dose gemcitabine with SBRT for LAPC...
  7. pmc The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway
    M Carla Cabrera
    Department of Oncology, Georgetown University, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 5:810-21. 2012
    ..In summary, the study distinguished CDK4 and phosphorylated pRb as targets for chemoprevention regimens targeting reversal of hyperplasia and dysplasia...